146 related articles for article (PubMed ID: 37632171)
21. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.
Sarayani A; Albogami Y; Thai TN; Smolinski NE; Patel P; Wang Y; Nduaguba S; Rasmussen SA; Winterstein AG
Am J Obstet Gynecol; 2022 Aug; 227(2):263.e1-263.e38. PubMed ID: 35032444
[TBL] [Abstract][Full Text] [Related]
22. [Isotretinoin (Roaccutane) in women of childbearing age: failure of following prescription guidelines].
Autret E; Radal M; Jonville-Béra AP; Goehrs JM
Ann Dermatol Venereol; 1997; 124(8):518-22. PubMed ID: 9740842
[TBL] [Abstract][Full Text] [Related]
23. Understanding and Responding to Prescribing Patterns of Sodium Valproate-Containing Medicines in Pregnant Women and Women of Childbearing Age in Western Cape, South Africa.
Mehta U; Smith M; Kalk E; Hayes H; Swart A; Tucker L; Coetzee R; Boulle A; Blockman M
Drug Saf; 2021 Jan; 44(1):41-51. PubMed ID: 32844313
[TBL] [Abstract][Full Text] [Related]
24. Antiseizure medications as migraine preventatives: a call for action for a teratogenic and neurodevelopmental risk removal.
Wells-Gatnik W; Martelletti P
Expert Opin Drug Saf; 2023; 22(9):777-781. PubMed ID: 37575009
[TBL] [Abstract][Full Text] [Related]
25. Changes in sodium valproate dispensing in women of childbearing age with a diagnosis of borderline personality disorder in Aotearoa New Zealand.
Tennant M; Frampton C; Mulder R; Eggleston K; Beaglehole B
N Z Med J; 2024 Jun; 137(1597):36-43. PubMed ID: 38901047
[TBL] [Abstract][Full Text] [Related]
26. [French Expert advice on the management of valproate in childbearing and pregnant women with bipolar disorder].
Samalin L; Arnould A; Boudieu L; Henry C; Haffen E; Drapier D; Anmella G; Pacchiarotti I; Vieta E; Belzeaux R; Llorca PM
Encephale; 2022 Dec; 48(6):624-631. PubMed ID: 36257849
[TBL] [Abstract][Full Text] [Related]
27. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data.
Teichert M; Visser LE; Dufour M; Rodenburg E; Straus SM; De Smet PA; Stricker BH
Drug Saf; 2010 Apr; 33(4):315-26. PubMed ID: 20297863
[TBL] [Abstract][Full Text] [Related]
28. Improving the Safety of Teratogen Prescribing Practices in a Pediatric Rheumatology Clinic.
Cooper AM; Horwitz M; Becker ML
Pediatrics; 2019 Apr; 143(4):. PubMed ID: 30837294
[TBL] [Abstract][Full Text] [Related]
29. Compliance with Prescribing and Dispensing Conditions for Valproate and Related Substances in Girls and Women of Childbearing Potential: A Survey of Community Pharmacists in France.
Fauvelle K; Bigna JJ
Drug Saf; 2023 Feb; 46(2):121-128. PubMed ID: 36287388
[TBL] [Abstract][Full Text] [Related]
30. [Prescribing valproate to girls and women of childbearing age in Germany : Analysis of trends based on claims data].
Wentzell N; Haug U; Schink T; Engel S; Liebentraut J; Linder R; Onken M; Schaefer C; Dathe K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Aug; 61(8):1022-1029. PubMed ID: 29922910
[TBL] [Abstract][Full Text] [Related]
31. National compliance with UK wide guidelines for usage of valproate in women of childbearing potential.
Eriksson SH; Tittensor P; Sisodiya SM
Seizure; 2022 May; 98():8-12. PubMed ID: 35395505
[TBL] [Abstract][Full Text] [Related]
32. The valproate prescription pattern for female mental healthcare users of reproductive age.
Gasa PS; Tomita A; Juby V; Paruk S
S Afr J Psychiatr; 2024; 30():2158. PubMed ID: 38628904
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of valproate prescriptions in women of childbearing age in certain regions of Russia.
Kostev K; Osina G; Rider F; Guekht A
Epilepsy Behav; 2019 Dec; 101(Pt A):106584. PubMed ID: 31675601
[TBL] [Abstract][Full Text] [Related]
34. Promoting safe prescribing in primary care with a contraceptive vital sign: a cluster-randomized controlled trial.
Schwarz EB; Parisi SM; Williams SL; Shevchik GJ; Hess R
Ann Fam Med; 2012; 10(6):516-22. PubMed ID: 23149528
[TBL] [Abstract][Full Text] [Related]
35. Evolution and characteristics of the use of valproate in women of childbearing age with bipolar disorder: Results from the FACE-BD cohort.
Samalin L; Godin O; Olié E; Etain B; Henry C; Pelletier A; Poinso F; Encely L; Mazer N; Roux P; Loftus J; Gard S; Bennabi D; Polosan M; Schwitzer T; Aubin V; Schwan R; Passerieux C; Bougerol T; Dubertret C; Aouizerate B; Haffen E; Courtet P; Bellivier F; Leboyer M; ; Llorca PM; Belzeaux R
J Affect Disord; 2020 Nov; 276():963-969. PubMed ID: 32745833
[TBL] [Abstract][Full Text] [Related]
36. Valproate in Pregnancy: Recent Research and Regulatory Responses.
Andrade C
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29873961
[TBL] [Abstract][Full Text] [Related]
37. Use of Valproate in Women: An Audit of Prescriptions to 10,001 Psychiatry, Neurology, and Neurosurgery Outpatients.
Andrade C; Jyothi SA; Renitha T; Anuroopa KP; Dona B; Basila T; Nimmy G
J Clin Psychiatry; 2021 Nov; 83(1):. PubMed ID: 34813688
[No Abstract] [Full Text] [Related]
38. The impact and challenges of the 2018 MHRA statement on the use of sodium valproate in women of childbearing age during the first year of implementation, in a UK epilepsy centre.
Davies P; Reuber M; Grunewald R; Howell S; Dickson J; Dennis G; Shanmugarajah P; Tsironis T; Brockington A
Seizure; 2020 Jul; 79():8-13. PubMed ID: 32380376
[TBL] [Abstract][Full Text] [Related]
39. Prescribing trends for sodium valproate in Ireland.
Murphy S; Bennett K; Doherty CP
Seizure; 2016 Mar; 36():44-48. PubMed ID: 26896815
[TBL] [Abstract][Full Text] [Related]
40. Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records.
Petersen I; McCrea RL; Sammon CJ; Osborn DP; Evans SJ; Cowen PJ; Freemantle N; Nazareth I
Health Technol Assess; 2016 Mar; 20(23):1-176. PubMed ID: 27029490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
